Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21604949rdf:typepubmed:Citationlld:pubmed
pubmed-article:21604949lifeskim:mentionsumls-concept:C0003826lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C0033572lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C1442792lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C0814812lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C1561577lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C1514811lld:lifeskim
pubmed-article:21604949lifeskim:mentionsumls-concept:C1706462lld:lifeskim
pubmed-article:21604949pubmed:dateCreated2011-5-24lld:pubmed
pubmed-article:21604949pubmed:abstractTextRadiotherapy (RT) always requires a compromise between tumor control and normal tissue side-effects. Technical innovation in radiation therapy (RT), such as three dimensional RT, is now established. Concerning prostate cancer (PC), it is reasonable to assume that RT of PC will increase in the future. The combination of small margins, a movable target (prostate), few fractions and high doses will probably demand dynamically positioning systems and in real time. This is called four dimensional radiotherapy (4DRT). Moreover, biological factors must be included in new treatments such as hypofractionation schedules. This new era is called five dimensional radiotherapy, 5DRT. In this paper we discuss new concepts in RT in respect to PC.lld:pubmed
pubmed-article:21604949pubmed:languageenglld:pubmed
pubmed-article:21604949pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21604949pubmed:citationSubsetIMlld:pubmed
pubmed-article:21604949pubmed:statusMEDLINElld:pubmed
pubmed-article:21604949pubmed:monthJunlld:pubmed
pubmed-article:21604949pubmed:issn1651-226Xlld:pubmed
pubmed-article:21604949pubmed:authorpubmed-author:NilssonStenSlld:pubmed
pubmed-article:21604949pubmed:authorpubmed-author:LennernäsBoBlld:pubmed
pubmed-article:21604949pubmed:authorpubmed-author:LevittSeymour...lld:pubmed
pubmed-article:21604949pubmed:authorpubmed-author:CastellanosEn...lld:pubmed
pubmed-article:21604949pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21604949pubmed:volume50 Suppl 1lld:pubmed
pubmed-article:21604949pubmed:ownerNLMlld:pubmed
pubmed-article:21604949pubmed:authorsCompleteYlld:pubmed
pubmed-article:21604949pubmed:pagination104-10lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:meshHeadingpubmed-meshheading:21604949...lld:pubmed
pubmed-article:21604949pubmed:year2011lld:pubmed
pubmed-article:21604949pubmed:articleTitleFour and five dimensional radiotherapy with reference to prostate cancer--definitions, state of the art and further directions--an overview.lld:pubmed
pubmed-article:21604949pubmed:affiliationDepartment of Oncology, Sahlgrenska Hospital and Academy, University of Gothenburg, Gothenburg, Sweden. bo.lennernas@telia.comlld:pubmed
pubmed-article:21604949pubmed:publicationTypeJournal Articlelld:pubmed